This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
TGTX Q1 Earnings Miss, Sales Rise Y/Y, Stock Up on Raised 2026 View
by Zacks Equity Research
TG Therapeutics misses Q1 earnings estimates, but strong Briumvi sales drive y/y revenues. Shares rise as the company raises 2026 revenue outlook.
AGENPositive Net Change AMRNPositive Net Change TGTXNegative Net Change ANABPositive Net Change
biotechs earnings
Mirum's Q1 Earnings & Revenues Beat Estimates, 2026 View Raised
by Zacks Equity Research
MIRM beats Q1 earnings and revenue estimates as Livmarli and bile acid drugs fuel growth, prompting a higher 2026 sales outlook.
INCYPositive Net Change AGENPositive Net Change ANABPositive Net Change MIRMPositive Net Change
biotechs earnings
UTHR Q1 Earnings Miss Estimates, Shares Jump on Strong Outlook
by Zacks Equity Research
United Therapeutics shares rise after Q1 earnings miss estimates as investors focus on Tyvaso IPF data and ralinepag's blockbuster potential.
UTHRPositive Net Change AMRNPositive Net Change INDVPositive Net Change
biotechs
ACAD Q1 Earnings & Revenues Miss Estimates Despite Y/Y Sales Growth
by Zacks Equity Research
Acadia's first-quarter earnings and revenues miss estimates despite 10% sales growth, driven by Nuplazid and Daybue demand.
INOPositive Net Change ACADPositive Net Change IMTXPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
by Zacks Equity Research
MDGL stock up on better-than-expected first-quarter results on account of robust Rezdiffra sales, driven by strong MASH demand and rising patient adoption.
INOPositive Net Change MDGLPositive Net Change IMTXPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
RXRX Q1 Loss Narrower Than Expected, Revenues Decline Y/Y
by Zacks Equity Research
Recursion Pharmaceuticals reports a narrower-than-expected Q1 loss, but revenues fall sharply as Roche collaboration income declines year over year.
INOPositive Net Change IMTXPositive Net Change RXRXPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
NVAX Q1 Earnings Beat, Stock Jumps 16% on Matrix-M Deal Momentum
by Zacks Equity Research
Novavax's shares rise 16% after Q1 earnings beat estimates as the company expands Matrix-M partnerships across oncology and infectious diseases.
SNYNegative Net Change PFEPositive Net Change NVAXPositive Net Change
biotechs earnings medical pharmaceuticals vaccines
Sarepta's Q1 Earnings & Sales Beat Estimates, '26 Outlook Maintained
by Zacks Equity Research
SRPT beats Q1 earnings and revenue estimates despite a sharp Elevidys sales drop, while maintaining its 2026 product revenue outlook.
RHHBYPositive Net Change SRPTNegative Net Change ARWRPositive Net Change
biotechs earnings gene-editing gene-therapy medical pharmaceuticals
CYTK Q1 Earnings Match Estimates, Revenues Beat on Myqorzo Launch
by Zacks Equity Research
Cytokinetics posts Q1 loss as Myqorzo launch lifts revenues to $19.4M, signaling commercial shift amid rising SG&A tied to rollout and expansion.
BMYPositive Net Change BAYRYPositive Net Change CYTKPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
OCGN Falls on Wider Q1 Loss Despite Strong Pipeline Progress Outlook
by Zacks Equity Research
Ocugen swings to a wider Q1 loss as costs climb, but pipeline milestones and gene therapy data keep its long-term plans on track.
CSTLPositive Net Change OCGNNegative Net Change INDVPositive Net Change
biotechs